China Biobetter EPO Deal Seen Boosting Genexine’s Prospects
This article was originally published in PharmAsia News
Executive Summary
Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.
You may also be interested in...
Should Pharma Be Concerned About Cooling China-Korea Ties?
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Setback For Athenex, Hanmi As CRL Requests New Trial
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Need a specific report? 1000+ reports available
Buy Reports